There are 1193 resources available
Introduction
Presenter: Christian Rolfo
Session: How do we best monitor patients during follow-up?
Resources:
Slides
Webcast
LBA57 - Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression
Presenter: Mariano Provencio Pulla
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Biomarkers of response to drugs and radiotherapy
Presenter: Benjamin Haibe-Kains
Session: Artificial Intelligence in prognostication
Resources:
Slides
Webcast
State-of-the-art in the treatment of advanced thyroid cancer
Presenter: Christine Spitzweg
Session: Bringing together thyroid cancer and neuroendocrine tumours
Resources:
Slides
Webcast
Minimalist or maximalist? From literature to real-world data
Presenter: Paolo Zola
Session: How do we best monitor patients during follow-up?
Resources:
Slides
Webcast
Optimal neo-adjuvant therapy in TNBC: Does one size fit all?
Presenter: Rebecca Dent
Session: Controversies in early stage triple negative breast cancer
Resources:
Slides
Webcast
Quality of life in IO-treated long-term survivors
Presenter: Lonneke Van De Poll-franse
Session: Long term survivors in the era of immunotherapy of cancer
Resources:
Slides
Webcast
How to use radiology in patients with hereditary syndromes
Presenter: Christina Messiou
Session: Genetic predisposition in patients with sarcoma
Resources:
Slides
Webcast
1264MO - IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)
Presenter: Nasser Altorki
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Cognitive defects in long term IO
Presenter: Anne Rogiers
Session: Long term survivors in the era of immunotherapy of cancer
Resources:
Slides
Webcast